SEARCH

SEARCH BY CITATION

References

  • Agresti, A. & Coull, B.A. (1998) Approximate is better than “exact” for interval estimation of binomial proportions. The American Statistician, 52, 119126.
  • Bornhauser, M., Kienast, J., Trenschel, R., Burchert, A., Hegenbart, U., Stadler, M., Baurmann, H., Schafer-Eckart, K., Holler, E., Kroger, N., Schmid, C., Einsele, H., Kiehl, M., Schwerdtfeger, R., Ganser, A., Dreger, P., Neubauer, A., Berdel, W.E., Ehninger, G., Beelen, D., Schetelig, J. & Stelljes, M. (2011) An intergroup randomised trial of standard intensity versus reduced intensity TBI-based conditioning in patients with acute myeloid leukemia in first complete remission. Blood (ASH Annual Meeting Abstracts), 118, 157.
  • Breems, D.A., Van Putten, W.L., De Greef, G.E., Van Zelderen-Bhola, S.L., Gerssen-Schoorl, K.B., Mellink, C.H., Nieuwint, A., Jotterand, M., Hagemeijer, A., Beverloo, H.B. & Lowenberg, B. (2008) Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. Journal of Clinical Oncology, 26, 47914797.
  • Bykov, V.J., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K.G. & Selivanova, G. (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nature Medicine, 8, 282288.
  • Cheson, B.D., Bennett, J.M., Kopecky, K.J., Buchner, T., Willman, C.L., Estey, E.H., Schiffer, C.A., Doehner, H., Tallman, M.S., Lister, T.A., Lo-Coco, F., Willemze, R., Biondi, A., Hiddemann, W., Larson, R.A., Lowenberg, B., Sanz, M.A., Head, D.R., Ohno, R. & Bloomfield, C.D. (2003) Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. Journal of Clinical Oncology, 21, 46424649.
  • Dohner, H., Estey, E.H., Amadori, S., Appelbaum, F.R., Buchner, T., Burnett, A.K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R.A., Lo-Coco, F., Naoe, T., Niederwieser, D., Ossenkoppele, G.J., Sanz, M.A., Sierra, J., Tallman, M.S., Lowenberg, B. & Bloomfield, C.D. (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, 115, 453474.
  • Fang, M., Storer, B., Estey, E., Othus, M., Zhang, L., Sandmaier, B.M. & Appelbaum, F.R. (2011) Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Blood, 118, 14901494.
  • Fenaux, P., Jonveaux, P., Quiquandon, I., Lai, J.L., Pignon, J.M., Loucheux-Lefebvre, M.H., Bauters, F., Berger, R. & Kerckaert, J.P. (1991) P53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood, 78, 16521657.
  • Finke, J., Bethge, W.A., Schmoor, C., Ottinger, H.D., Stelljes, M., Zander, A.R., Volin, L., Ruutu, T., Heim, D.A., Schwerdtfeger, R., Kolbe, K., Mayer, J., Maertens, J.A., Linkesch, W., Holler, E., Koza, V., Bornhauser, M., Einsele, H., Kolb, H.J., Bertz, H., Egger, M., Grishina, O. & Socie, G. (2009) Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology, 10, 855864.
  • Grimwade, D., Hills, R.K., Moorman, A.V., Walker, H., Chatters, S., Goldstone, A.H., Wheatley, K., Harrison, C.J. & Burnett, A.K. (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood, 116, 354365.
  • Haferlach, C., Dicker, F., Herholz, H., Schnittger, S., Kern, W. & Haferlach, T. (2008) Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia, 22, 15391541.
  • Ito, D., Albers, A., Zhao, Y.X., Visus, C., Appella, E., Whiteside, T.L. & DeLeo, A.B. (2006) The wild-type sequence (wt) p53(25–35) peptide induces HLA-DR7 and HLA-DR11-restricted CD4+ Th cells capable of enhancing the ex vivo expansion and function of anti-wt p53(264–272) peptide CD8+ T cells. Journal of Immunology, 177, 67956803.
  • Long, J., Parkin, B., Ouillette, P., Bixby, D., Shedden, K., Erba, H., Wang, S. & Malek, S.N. (2010) Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood, 116, 7180.
  • Nahi, H., Merup, M., Lehmann, S., Bengtzen, S., Mollgard, L., Selivanova, G., Wiman, K.G. & Paul, C. (2006) PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. British Journal of Haematology, 132, 230236.
  • Nahi, H., Lehmann, S., Bengtzen, S., Jansson, M., Mollgard, L., Paul, C. & Merup, M. (2008a) Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia. Leukaemia & Lymphoma, 49, 508516.
  • Nahi, H., Selivanova, G., Lehmann, S., Mollgard, L., Bengtzen, S., Concha, H., Svensson, A., Wiman, K.G., Merup, M. & Paul, C. (2008b) Mutated and non-mutated TP53 as targets in the treatment of leukaemia. British Journal of Haematology, 141, 445453.
  • Nigro, J.M., Baker, S.J., Preisinger, A.C., Jessup, J.M., Hostetter, R., Cleary, K., Bigner, S.H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F.S., Weslon, A., Modali, R., Harris, C.C. & Vogelstein, B. (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature, 342, 705708.
  • Parmentier, S., Bornhauser, M., Thiede, C., Rollig, C., Kramer, M., Haenel, M., Herbst, R., Schmitz, N., Stuhlmann, R., Wandt, H., Schafer-Eckart, K., Aulitzky, W.E., Kaufmann, M., Ho, A.D., Kramer, A., Berdel, W.E., Muller-Tidow, C., Serve, H., Ehninger, G. & Schaich, M. (2011) No benefit of combining additional compounds with standard high dose cytarabine consolidation: results of the prospective randomized AML2003 study. Blood (ASH Annual Meeting Abstracts), 118, 255.
  • Platzbecker, U., Thiede, C., Fussel, M., Geissler, G., Illmer, T., Mohr, B., Hanel, M., Mahlberg, R., Krumpelmann, U., Weissinger, F., Schaich, M., Theuser, C., Ehninger, G. & Bornhauser, M. (2006) Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia, 20, 707714.
  • Popowicz, G.M., Czarna, A., Rothweiler, U., Szwagierczak, A., Krajewski, M., Weber, L. & Holak, T.A. (2007) Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle, 6, 23862392.
  • Rollig, C., Kramer, M., Hanel, M., Herbst, R., Schmitz, N., Bodenstein, H., Pfluger, K.-H., Wagner, T., Wolf, M., Bornhauser, M., Thiede, C., Schaich, M., Platzbecker, U., Stolzel, F., von Bonin, M., Wandt, H., Ehninger, G. & Schuler, U. (2010) Induction treatment in elderly patients with acute myeloid leukemia (AML): randomized comparison of intermediate-dose cytarabine plus mitoxantrone (IMA) versus standard-dose cytarabine plus daunorubicin (DA) In 492 AML patients >60 years – results from the SAL 60plus trial. Blood (ASH Annual Meeting Abstracts), 116, 334.
  • Rücker, F.G., Schlenk, R.F., Bullinger, L., Kayser, S., Teleanu, V., Kett, H., Habdank, M., Kugler, C.M., Holzmann, K., Gaidzik, V.I., Paschka, P., Held, G., von Lilienfeld-Toal, M., Lübbert, M., Fröhling, S., Zenz, T., Krauter, J., Schlegelberger, B., Ganser, A., Lichter, P., Döhner, K. & Döhner, H. (2012) TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood, 119, 21142121.
  • Schaich, M., Rollig, C., Soucek, S., Kramer, M., Thiede, C., Mohr, B., Oelschlaegel, U., Schmitz, N., Stuhlmann, R., Wandt, H., Schafer-Eckart, K., Aulitzky, W., Kaufmann, M., Bodenstein, H., Tischler, J., Ho, A., Kramer, A., Bornhauser, M., Schetelig, J. & Ehninger, G. (2011) Cytarabine dose of 36 g/m(2) compared with 12 g/m(2) within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. Journal of Clinical Oncology, 29, 26962702.
  • Schlenk, R.F., Dohner, K., Mack, S., Stoppel, M., Kiraly, F., Gotze, K., Hartmann, F., Horst, H.A., Koller, E., Petzer, A., Grimminger, W., Kobbe, G., Glasmacher, A., Salwender, H., Kirchen, H., Haase, D., Kremers, S., Matzdorff, A., Benner, A. & Dohner, H. (2010) Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. Journal of Clinical Oncology, 28, 46424648.
  • Seifert, H., Mohr, B., Thiede, C., Oelschlagel, U., Schakel, U., Illmer, T., Soucek, S., Ehninger, G. & Schaich, M. (2009) The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia. Leukemia, 23, 656663.
  • Shaffer, L.G., Slovak, M.L. & Campbell, L.J. (2009) ISCN (2009): An International System for Human Cytogenetic Nomenclature. S. Karger, Basel.
  • Slovak, M.L., Kopecky, K.J., Cassileth, P.A., Harrington, D.H., Theil, K.S., Mohamed, A., Paietta, E., Willman, C.L., Head, D.R., Rowe, J.M., Forman, S.J. & Appelbaum, F.R. (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood, 96, 40754083.
  • Snyder, E.L., Meade, B.R., Saenz, C.C. & Dowdy, S.F. (2004) Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biology, 2, E36.
  • Soenen, V., Preudhomme, C., Roumier, C., Daudignon, A., Lai, J.L. & Fenaux, P. (1998) 17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. Blood, 91, 10081015.
  • Suciu, S., Mandelli, F., de Witte, T., Zittoun, R., Gallo, E., Labar, B., De Rosa, G., Belhabri, A., Giustolisi, R., Delarue, R., Liso, V., Mirto, S., Leone, G., Bourhis, J.H., Fioritoni, G., Jehn, U., Amadori, S., Fazi, P., Hagemeijer, A. & Willemze, R. (2003) Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood, 102, 12321240.
  • Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B.T., Qing, W., Packman, K., Myklebost, O., Heimbrook, D.C. & Vassilev, L.T. (2006) Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proceedings of the National Academy of Sciences of the United States of America, 103, 18881893.
  • Vousden, K.H. & Lu, X. (2002) Live or let die: the cell's response to p53. Nature Reviews Cancer, 2, 594604.